Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danqi-Tongluo decoction is a Traditional Chinese Medicine (TCM) herbal formula primarily used for the treatment of cervical spondylosis. The formula's name is derived from its two primary constituent herbs: *Salvia miltiorrhiza* (Danshen) and *Panax notoginseng* (Sanqi). In TCM theory, these ingredients are utilized to promote blood circulation, resolve blood stasis, and unblock the collaterals (Tongluo), which are essential for addressing the underlying pathology of cervical spondylosis, particularly the vertebral artery type. The decoction is typically administered orally and is often evaluated in clinical settings in combination with other TCM modalities, such as electroacupuncture, to alleviate symptoms like neck pain, dizziness, and functional impairment. It is currently being studied in clinical trials sponsored by institutions such as Longhua Hospital, Shanghai University of Traditional Chinese Medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danqi-Tongluo decoction.